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 Allogeneic PICs express and secrete an
array of pro-regenerative paracrine
factors that stimulate a regenerative
response in a preclinical muscle injury
model applicable to humans.
 Paracrine factors secreted by allogeneic
PICs stimulate endogenous progenitor
cell activation and differentiation, leading
to accelerated and improved myoﬁber
regeneration and microvessel formation.
 Allogeneic PICs survive long enough to
exert their action before being cleared by
the host immune system. Therefore, the
cells transplanted are allogeneic but the
regeneration is completely autologous.
 Administration of HGF and IGF-1 improves
skeletal muscle regeneration, but not to
the same extent as PIC transplantation.
ABBR EV I A T I ON S
AND ACRONYMS
BrdU = 5-bromo-20-deoxyuridine
CM = pPIC conditioned medium
CSA = cross sectional area
CSC = cardiac stem cell
CTRL = control
CTX = cardiotoxin
FBS = fetal bovine serum
DAPI = 40 ,6-diamidino-2-
phenylindole
DMEM = Dulbecco’s Modiﬁed
Eagle’s medium
GFPpPIC = GFP-positive porcine
PW1pos/Pax7neg interstitial cell
GM = growth medium
HUVEC = human umbilical vein
endothelial cell
HVG = hematoxylin and
van Gieson
ICM = heat-inactivated
conditioned medium
IV = intravenous
MHC = myosin heavy chain
MI = myocardial infarction
nMHC = neonatal myosin
heavy chain
P = passage
PBMC = peripheral blood
mononuclear cell
PBS = phosphate buffered saline
PIC = PW1pos/Pax7neg
interstitial cell
pPIC = porcine PW1pos/Pax7neg
interstitial cell
qRT-PCR = quantitative
reverse transcription
polymerase chain reaction
TA = tibialis anterior
UM = unconditioned medium
vWF = Von Willebrand factor
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t reSkeletal muscle-derived PW1pos/Pax7neg interstitial cells (PICs) express and secrete a multitude of prorege-
nerative growth factors and cytokines. Utilizing a porcine preclinical skeletal muscle injury model, delivery of
allogeneic porcine PICs (pPICs) signiﬁcantly improved and accelerated myoﬁber regeneration and neocapilla-
rization, compared with saline vehicle control-treated muscles. Allogeneic pPICs did not contribute to new
myoﬁbers or capillaries and were eliminated by the host immune system. In conclusion, allogeneic pPIC
transplantation stimulated the endogenous stem cell pool to bring about enhanced autologous skeletal muscle
repair and regeneration. This allogeneic cell approach is considered a cost-effective, easy to apply, and readily
available regenerative therapeutic strategy. (J Am Coll Cardiol Basic Trans Science 2017;2:717–36)
© 2017 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).S keletal muscle is a dynamic, highlyplastic tissue that is capable of under-going repair and regeneration in
healthy individuals (1). However, this regen-
erative capacity can become impaired in
muscle diseases, such as muscular dystro-
phy, and as a result of disuse and ageing
(2,3). This leads to decreased proliferation,
delayed fusion, and reduced differentiation
of muscle progenitors, as well as a gradual
replacement of muscle ﬁbers by fat and
ﬁbrosis with poor vascularization (4,5). The
mechanisms that underpin impaired skeletal
muscle regeneration are still unclear; how-
ever, recent ﬁndings suggest that the micro-
environment and/or systemic factors (6,7)
affect the response of various endogenous
skeletal muscle progenitor cells to repair
and regenerate after injury (8). This has led
us to focus upon therapeutic strategies that
target resident muscle progenitors and stim-
ulate endogenous repair mechanisms.
Autologous stem cell approaches are
attractive from a theoretical and biological
standpoint; however, for skeletal muscle
where the muscle satellite cells cannot beool of Basic & Medical Biosciences, Centre of Human & Aerospa
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ceived March 17, 2017; revised manuscript received August 16effectively propagated to large numbers in vitro, and
like other tissue-speciﬁc stem/progenitor cells, such
as cardiac, are affected by age and disease, they are
impractical. Moreover, administration of cells can
induce therapeutic responses by indirect means, such
as secretion of growth factors and interaction with
endogenous repair processes, represented by the
resident stem/progenitor cells (9,10). This has been
termed the paracrine effect. Therefore, there seems to
be little advantage in the use of autologous cells
because a similar, and perhaps enhanced, effect can
be obtained by the administration of a cell type iso-
lated from allogeneic sources, which could be made
readily available at reduced costs (11). We have pre-
viously shown that intracoronary injection of alloge-
neic porcine cardiac stem cells (CSCs) after
myocardial infarction (MI) activates the endogenous,
resident CSCs through a paracrine mechanism,
resulting in improved myocardial cell survival, func-
tion, remodeling, and regeneration (12).
Skeletal muscle satellite cells, although capable of
muscle ﬁber regeneration, have a limited migration
capacity with an inability to cross the endothelial wall
(13). Moreover, cultured satellite cells ex vivo have
decreased stemness, proliferation, and myoﬁber dif-
ferentiation, which has subsequently hampered theirce Physiological Sciences & Centre for Stem Cells and
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and Nutrition, Université de Pierre et Marie Curie,
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719translation (14). In recent years, skeletal muscle has
been shown to harbor other stem/progenitor cells,
such as the PW1pos/Pax7neg interstitial cells (PICs),
which are bipotent, giving rise to new skeletal muscle
ﬁbers and vasculature-associated cell types in vitro
and in vivo (15,16). Unlike the satellite cells, we have
shown that porcine PICs (pPICs) can be successfully
isolated and propagated in vitro up to passage 40
(P40) while maintaining a stable phenotype/genotype
(16). Therefore PICs represent an attractive and
alternative cell source for regenerative therapies.
The pig represents an excellent biological model for
human biomedical preclinical research due to its
anatomic, physiological, pathological, and genomic
similarities to humans (17). In terms of porcine skeletal
muscle biology, considerable correlation between
contractile, metabolic, and morphological features to
human skeletal muscle exist (18–20). Although small
animal models are a valuable resource, they do not
always accurately reﬂect the clinical manifestation,
with many cell therapies that have been shown to be
highly effective in small animalmodels (21,22) yielding
only modest therapeutic value in human clinical trials
(23,24). Combined with the 3 orders of magnitude
difference in mass between rodent models and
humans, there is an obvious need to test cell therapies
in more illustrative animal models. Developing a
porcine preclinical model for skeletal muscle regen-
eration can provide a useful link between the
widely used rodent models and humans so that
an improved prediction of therapeutic efﬁcacy of
therapies can be achieved and successfully translated
to patients. Moreover, unlike other organs, skeletal
muscle is an efﬁcient regenerative tissue yielding
adequate resident progenitor cells, which give rise to
new myoﬁbers and vasculature following injury.
Altogether, this makes the porcine skeletal muscle
an appropriate model system to test proof-of-concept
regenerative therapeutic approaches, such as the
allogeneic cell approach, described here for the
ﬁrst time to our knowledge. Allogeneic stem cell
therapy is conceptually and practically different from
any presently in clinical use and could be applied in the
repair and regeneration of other tissues, such as
the heart.
Here, we tested the therapeutic reparative effect of
delivering allogeneic pPICs to the injured pig skeletal
muscle. We hypothesized that allogeneic pPICs
transplanted following skeletal muscle injury would
supply regenerative bioactive factors capable of acti-
vating the endogenous stem/progenitor cells,
enhancing and accelerating the regeneration of
damaged skeletal muscle tissue. It was also hypoth-
esized that the allogeneic pPICs survive long enoughin the allogeneic host to produce their paracrine
effect activating the endogenous target cells before
being eliminated by the host immune system.
Therefore, the cells transplanted are allogeneic, but
the regeneration is completely autologous.
METHODS
STUDY DESIGN, SKELETAL MUSCLE INJURY, AND
INTRAMUSCULAR pPIC ADMINISTRATION. Animals
were immune competent, 2-month-old (juvenile),
female, large Dalland Landrace pigs (32  5 kg). All
animal procedures were performed in accordance
with the EU Directive guidelines and regulations for
animal experimentation by appropriately qualiﬁed
staff and approved by the institutional animal welfare
and ethical review board DEC Utrecht, the
Netherlands. Pigs were sedated with 4 mg/kg thio-
pental sodium, and anesthesia was maintained with
midazolam (0.5 mg/kg/h) via an intravenous (IV)
catheter placed in a peripheral ear vein before intu-
bation. The animals were subsequently moved to the
surgery room and secured to the surgical table with
limb bindings. The lower hind limb was shaved and
disinfected using iodine before surgery.
The ﬁrst phase of the in vivo study used 6 pigs. In
order to assess 2 different injury models, either an
open freeze/crush (n ¼ 3) or cardiotoxin (CTX) injury
(n ¼ 3) of the tibialis anterior (TA) muscle was sub-
sequently performed. Brieﬂy, a 5-cm longitudinal
incision of the skin and underlying fascia was made
along the anterior aspect of the distal limb. The skin
and fascia were retracted, the TA muscle located,
nonabsorbable Prolene sutures (Ethicon, Somerville,
New Jersey) were used to mark the injury site (1 cm 
1 cm2), and the injury was induced. In the case of
freeze/crush injury, the muscle was crushed with
forceps (Fine Science Tools, Foster City, California),
pre-cooled in liquid nitrogen. This procedure was
repeated 7 times for 5 s each, in direct continuity with
the respective distal crush in the deﬁned area. In the
case of CTX injury induction, a 10 mmol/l CTX solu-
tion, Naja mossambica mossambica (Sigma-Aldrich,
St. Louis, Missouri), was ﬁltered and brought to room
temperature before injection. The CTX was dispersed
in a series of 5 intramuscular injections using a 25-ga
needle to deliver a total volume of 500 ml to the pre-
deﬁned area. The contralateral leg served as a sham
control (CTRL) and was treated identically; however,
no injury was applied in the case of freeze/crush, or
phosphate buffered saline (PBS) alone was injected in
animals receiving the CTX injury. The injury area was
identiﬁed through marking with sutures. After injury
induction, the superﬁcial skin was sutured; animals
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720were allowed to recover and then sacriﬁced by anes-
thetic overdose at either 14 or 21 days post-injury.
In the second phase of the in vivo study, 10 pigs
were randomly assigned to receive either saline
vehicle (PBS) or allogeneic GFPpos pPICs, 15 min post-
CTX injury. GFPpos pPICs were propagated and cryo-
stored between P3 and P12. Before transplantation,
GFPpos pPICs were pre-mixed, brought into suspen-
sion, centrifuged, washed twice with PBS, and then
counted. A total of 20  106 GFPpos pPICs were
resuspended in 500 ml of PBS and injected intramus-
cularly into the injured TA through a 25-ga needle
(n ¼ 5). Control animals were treated identically;
however, 500 ml of PBS alone was injected (n ¼ 5).
Both treatments were distributed across 5 injection
sites to the injury site. The contralateral control leg of
each animal served as a sham CTRL and received no
injury, only PBS, using the same protocol.
In separate pigs, local delivery of human recom-
binant insulin-like growth factor (IGF)-1 (8 mg) and
hepatocyte growth factor (HGF) (2 mg) (Peprotech,
Rocky Hill, New Jersey) was achieved by diluting
both growth factors in a total volume of 500 ml of PBS
before being dispersed in a series of 5 intramuscular
injections using a 25-ga needle to deliver the total
volume to the pre-deﬁned injured area (n ¼ 5). In the
case of ureido-pyrimidinone (UPy)þIGF-1/HGF treat-
ment, the UPy hydrogelators were synthesized by
SyMO-Chem BV (Eindhoven, the Netherlands), as
described previously (25). To prepare the hydrogel,
polymer solutions were dissolved at 10% by weight
in PBS by stirring at 70C for 1 h and were subse-
quently cooled to room temperature. To liquefy the
polymer solution, the pH was increased to pH 8.5 by
adding 2-ml aliquots of a 0.1 mol/l NaOH stock solu-
tion. The hydrogel was then sterilized with ultravi-
olet light for 1 h, and human recombinant IGF-1 and
HGF were added before use, yielding a ﬁnal con-
centration of 8 mg and 2 mg, respectively. A total
volume of 500 ml of UPy hydrogelþIGF-1/HGF was
administered as per the method described in the
preceding text (n ¼ 5).
In order to track newly formed cells post-injury,
we used the thymidine analogue, 5-bromo-
20-deoxyuridine (BrdU). In order to deliver BrdU to the
animals over the course of the regeneration period, we
used an IV delivery system. This involved making a
channel through the pig’s neck musculature and
feeding an IV line through, which was subsequently
connected to the jugular vein. This enabled us to access
a cannula situated on the dorsal aspect of the pig’s
neck, which was directly linked to circulation system.
This method allowed daily administration of BrdU at a
dose of 10 mg/kg/day without the need to sedate theanimals. Animals were sacriﬁced by anesthetic over-
dose at 14 days post-injury.
CELL CULTURE. Porcine PICs were isolated and
maintained as previously described (16) in growth
medium (GM); Dulbecco’s Modiﬁed Eagle’s medium/
Ham’s F12 (DMEM/F12; Sigma-Aldrich): Neurobasal A
(Thermo Fisher Scientiﬁc, Waltham, Massachusetts)
medium (1:1) containing 10% embryonic stem cell
qualiﬁed fetal bovine serum (ESQ-FBS) (Invitrogen,
Carlsbad, California), B-27 and N-2 supplements
(Thermo Fisher Scientiﬁc), leukemia inhibitory factor
(LIF) (10 ng/ml; Millipore, Billerica, Massachusetts),
basic ﬁbroblast growth factor (bFGF) (10 ng/ml;
Peprotech), epidermal growth factor (EGF)
(20 ng/ml; Peprotech), insulin-transferrin-selenium
2% GlutaMAX (Thermo Fisher Scientiﬁc), 1%
penicillin-streptomycin (Thermo Fisher Scientiﬁc),
and 0.1% gentamicin (10 mg/ml; Thermo Fisher Scien-
tiﬁc). Myogenic differentiation was induced by
replacing GM with DMEM/F12, 2% horse serum 2%
GlutaMAX (Thermo Fisher Scientiﬁc) for either 24 h
or 5 days. Human myoblasts were isolated and
maintained as previously described (26). Human
umbilical vein endothelial cells (HUVECs) (Lonza,
Basel, Switzerland) were cultured in endothelial
cell GM supplemented with 2% FBS and growth
factors (Lonza).
GFP TRANSDUCTION OF pPICs. To generate green
ﬂuorescent protein (GFP) lentivirus, HEK293T cells
were cultured overnight in dishes pre-coated with 0.1
mg/ml collagen solution (Sigma-Aldrich) in DMEM,
10% fetal calf serum (FCS), 2% GlutaMAX, and 1%
penicillin-streptomycin until 70% conﬂuent. The
following day, a mix of 6.5 mg of pCMV D8.9 packaging
plasmid, 3.5 mg VSV-g envelope plasmid, and 10 mg GFP
expression construct were diluted in 500 ml of
OptiMEM-1 (Thermo Fisher Scientiﬁc) without FCS or
antibiotics. A second mixture, containing 30 ml of
Lipofectamine 2000 (Thermo Fisher Scientiﬁc) in
500 ml of OptiMEM-1 without FCS or antibiotics was
added to the plasmid mix solution and incubated at
room temperature for 20 min, inverting the tube every
5 min. The plasmid/Lipofectamine mixture was added
dropwise to the HEK293T cells and incubated at 37C
for 4 h. After 4 h, an equal volume of OptiMEM-1 with
the addition of 10% FCS and 1% penicillin-
streptomycin was added. The supernatant was
collected 48 h post-transfection and ﬁltered with a
0.45-mm ﬁlter. The viral supernatant was subse-
quently concentrated using a Lenti-X Concentrator kit
(Clontech, Mountain View, California) according to the
manufacturer’s speciﬁcation, and the viral titer was
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721measured using GoStix (Clontech). The pseudovirus
was subsequently used for transduction or stored
at 80C. Target pPICs at P2 were transduced by
adding 30 ml/ml pseudovirus in DMEM, 10% FCS con-
taining 12 mg/ml polybrene (Sigma-Aldrich). After 24 h,
the medium was changed to DMEM with the addition
of serum and antibiotics. The infected target cells were
further cultured and analyzed at 24 h post-
transduction for GFP expression, using ﬂuorescent
microscopy and ﬂow cytometry. Porcine PICs trans-
duced with the GFP reporter gene were propagated for
allogeneic transplantation experiments in pPIC GM.
FLOW CYTOMETRY. Flow cytometry was performed
as previously described (16). Immunophenotyping
was performed using the following antibodies; PW1
(antibody kindly gifted by D. Sassoon), CD34 (Thermo
Fisher Scientiﬁc), CD45 (AbD Serotec, Puchheim,
Germany), and Pax7 (Developmental Studies Hybrid-
oma Bank, Iowa City, Iowa). Isotype controls were
used to deﬁne the speciﬁc gates and analysis was
performed using a FACSCanto II with FACSDiva
software (BD Biosciences, San Jose, California).
TISSUE PROCESSING AND HISTOLOGY. Whole TA
muscles were excised, washed in PBS, weighed, and
then ﬁxed in 10% formalin (Sigma-Aldrich) with
gentle agitation for 4 days. Muscles were processed
for parafﬁn embedding using a Leica TP1020 tissue
processor (Leica Biosystems, Buffalo Grove, Illinois)
as previously described (16). To measure myoﬁber
diameter and identify ﬁbrosis, muscle sections were
stained with hematoxylin and van Gieson (HVG)
(Sigma-Aldrich), respectively, according to standard
procedures (27). Cross-sectional area (CSA) of con-
nective tissue was determined from 5 ﬁelds of view
at 20 magniﬁcation per muscle using a light
microscope (Olympus, Tokyo, Japan) and ImageJ2
software (NIH, Bethesda, Maryland). To determine
the mean myoﬁber diameters, measurements were
performed on transverse sections with 100 myoﬁbers
analyzed per section.
IMMUNOHISTOCHEMISTRY/IMMUNOCYTOCHEMISTRY.
To identify regenerating muscle ﬁbers, muscle sec-
tions were stained with anti-human neonatal myosin
heavy chain (nMHC) (Developmental Studies
Hybridoma Bank). Sections were also stained with
anti-laminin (Abcam, Cambridge, United Kingdom) to
identify the basal lamina of individual ﬁbers and
centralized nuclei identiﬁed through 40,6-diamidino-
2-phenylindole (DAPI) (Sigma-Aldrich) staining. All
newly formed cells were identiﬁed by anti-BrdU
(Roche, Basel, Switzerland) staining. The number of
centralized nuclei was determined by counting5 ﬁelds/section at 20 magniﬁcation. A total of 5
slides/animal were assessed capillary density was
evaluated by staining with an antibody against
von Willebrand factor (vWF) (Dako, Glostrup,
Denmark). The number of capillaries (deﬁned as 1 or 2
endothelial cells spanning the vWF-positive vessel
circumference) was determined by counting 5 ﬁelds/
section at 20 magniﬁcation. A total of 5 slides/animal
was assessed, and the amount of capillaries was
expressed per number of myoﬁbers. Double staining
for BrdU/vWF was performed to identify newly
formed capillaries and counterstained with DAPI to
detect nuclei. Tracking of donor GFPpos cells was
achieved by staining with anti-GFP (Rockland,
Limerick, Pennsylvania). GFPpos cells were quantiﬁed
by counting 5 ﬁelds/section at 20 magniﬁcation. A
total of 5 slides/animal were assessed, and the number
of GFPpos cells quantiﬁed. To identify whether trans-
planted cells retained their PIC phenotype in vivo,
tissue sections were stained for PW1 (antibody kindly
gifted by D. Sassoon) and Pax7 (Developmental
Studies Hybridoma Bank). Bipotent myogenic differ-
entiation was assessed by staining for myosin heavy
chain (MHC) (Developmental Studies Hybridoma
Bank) and smooth muscle actin (Sigma-Aldrich) as
previously described (16). Immune cells were identi-
ﬁed by staining with anti-CD8a (Abcam), anti-
Granzyme B (Abcam) or anti–IBA-1 (Wako, Osaka,
Japan). Immune cells were quantiﬁed by imaging 5
ﬁelds/section at 20 magniﬁcation. All secondary
antibodies were purchased from Thermo Fisher
Scientiﬁc. In all cases, an ApoTome ﬂuorescent mi-
croscope (Carl Zeiss, Oberkochen, Germany) was used
to obtain images for quantiﬁcation and representative
images were acquired using a confocal microscope
(Nikon A1R, Nikon, Tokyo, Japan). Analysis was sub-
sequently performed using ImageJ software.
GENE EXPRESSION PROFILING. To identify growth
factors and cytokines expressed by undifferentiated
and early myogenic differentiated pPICs, gene array
analyses were performed (n ¼ 3/group). RNA was
extracted from pPICs that were either maintained in
an undifferentiated condition in standard GM or
placed in a myogenic permissive environment
(DMEM/F12, 2% horse serum) for 24 h. Total RNA was
isolated using the Qiagen RNeasy Mini Kit and reverse
transcribed using the RT2 ﬁrst strand kit (Qiagen,
Hilden, Germany) according to the manufacturer’s
recommendations for the RT2 Proﬁler PCR Array.
Quantitative reverse transcription polymerase chain
reaction (qRT-PCR) was then performed using RT2
SYBR Green (Qiagen) and the RT2 Proﬁler PCR Array
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722(Qiagen), which was custom designed for the identi-
ﬁcation of porcine growth factors and cytokines of
interest. Brieﬂy, samples were denatured for 10 min
at 95C, cycled 40 times at 95C for 15 s, followed by
40 cycles at the annealing temperature of 60C for
1 min on a MyIQ thermocycler (Bio-Rad, Hercules,
California). All reactions were carried out in triplicate;
data were normalized to 5 housekeeping genes
(ACTB, B2M, GAPDH, HPRT1, RPL13A) and analyzed
using Bio-Rad IQ software (version 3.1).
WESTERN BLOTTING. Immunoblots were carried out
using protein lysates obtained from undifferentiated
pPICs and pPICs that had undergone early myogenic
differentiation (n ¼ 3/group). Approximately, 50 mg of
protein were separated on gradient (10% to 15%) SDS-
polyacrylamide gels. After electrophoresis, proteins
were transferred onto nitrocellulose membranes and
blocked with 5% milk, then incubated with antibodies
against IGF-1 (Santa Cruz Biotechnology, Dallas,
Texas), HGF (Santa Cruz Biotechnology), transforming
growth factor (TGF)-b1 (Santa Cruz Biotechnology),
neuregulin (NRG)-1 (Santa Cruz Biotechnology) at
dilutions suggested by the manufacturers. GAPDH
(Millipore) was used as a loading control. Proteins
were detected by chemiluminescence using horse-
radish peroxidase–conjugated secondary antibodies
(Santa Cruz Biotechnology) and visualized using ECL
PlusWestern Blotting Detection Reagents (Amersham,
Little Chalfont, United Kingdom) and a Chemidoc
imaging system (Bio-Rad).
BRDU PROLIFERATION ASSAY IN VITRO. pPICs and
human myoblasts were plated in 24-well plates at a
density of 5  103 per well and were serum starved for
6 h in 0% serum DMEM/F12 medium. To investigate
the effect of pPIC conditioned media on proliferation,
wells were either supplemented with standard GM,
unconditioned medium (UM), pPIC conditioned me-
dium (CM), or heat-inactivated conditioned medium
(ICM). Each well was supplemented with BrdU
(1 mg/ml) every 8 h, ﬁxed in 4%paraformaldehyde after
24 h, and BrdU incorporation was then assessed using
the BrdU detection kit (Roche) (n ¼ 3/condition).
In order to investigate the effect of growth factors
on pPIC proliferation, wells were serum starved for
6 h and then switched to basal media (control), or
supplemented with IGF-1 (100 ng/ml; Peprotech), HGF
(100 ng/ml; Peprotech), NRG-1 (100 ng/ml; R&D Sys-
tems, Minneapolis, Minnesota), or TGF-b1 (5 ng/ml;
Peprotech). Each well was supplemented with BrdU
(1 mg/ml) every 8 h, ﬁxed after 24 h, and BrdU
incorporation was assessed using the BrdU detec-
tion kit (Roche) (n ¼ 3/growth factor). Nuclei were
counterstained with DAPI. Cells were evaluatedusing an ApoTome ﬂuorescent microscope (Carl
Zeiss). The percentage of BrdUpos cells relative to
the total number of cells was determined by
counting 5 random ﬁelds at 20 magniﬁcation for
each dish, and then expressed as fold change over
unsupplemented control.
MYOGENIC DIFFERENTIATION ASSAY IN VITRO. To
assess the effect of different growth factors in the
induction of myogenic differentiation in vitro, 1  104
pPICs were plated in 24-well plates on gelatin-coated
coverslips in basal media (control). Individual growth
factors (concentrations stated earlier in the text)
were supplemented (n ¼ 3 wells/growth factor).
Three wells acted as controls, with no growth factors
added to the medium. Cells were ﬁxed in 4%
paraformaldehyde after 5 days, and myogenic differ-
entiation was quantiﬁed by staining for MHC
(Developmental Studies Hybridoma Bank). Nuclei
were counterstained with DAPI. Cells were evaluated
using an ApoTome ﬂuorescent microscope (Carl
Zeiss), 5 random ﬁelds at 20 magniﬁcation were
quantiﬁed for each well, and the fusion index was
calculated by counting the number of nuclei inside
myotubes per total nuclei.
MATRIGEL ANGIOGENESIS ASSAY. To study angio-
genesis, 150 ml of Matrigel substrate (Corning, Corn-
ing, New York) diluted with DMEM (1:10) was pipetted
into each well of a 24-well plate and allowed to
solidify for 1 h at 37C. Thereafter, 2  104 HUVECs
were seeded into each well in either endothelial GM
(see details earlier in the text), UM (serum-free), CM,
or ICM. Cells were imaged at 24 h using a light mi-
croscope (Olympus). Five ﬁelds of view at 20
magniﬁcation were imaged for each condition.
Parameters of angiogenesis (capillary area, number of
tubes per ﬁeld of view, tube length, and branching
points) were analyzed using Wimasis image analysis
software (WimTube Release 4.0, Onimagin Technol-
ogies, Córdoba, Spain).
CYTOTOXICITY ASSAY IN VITRO. Peripheral blood
mononuclear cells (PBMCs) were isolated from pig
whole blood using density gradient centrifugation
with Histopaque (Sigma-Aldrich). Brieﬂy, whole
blood was diluted at the ratio of 1:1 with PBS and
carefully layered over 6 ml of Histopaque solution.
Tubes were centrifuged at 400  g for 30 min at room
temperature. PBMCs were then carefully collected
from the buffy coat layer, washed twice with PBS, and
frozen at 80C until ready to use. PBMCs were
resuscitated and cultured for 3 days in RPMI 1640
GlutaMAX medium (Thermo Fisher Scientiﬁc), 10%
FBS, and 1% penicillin-streptomycin (Thermo Fisher
Scientiﬁc). PBMCs were either maintained in medium
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723alone or activated with phytohemagglutinin (PHA)
(Sigma-Aldrich) (5 mg/ml) for 3 days. PICs (P6) were
plated at 1 105 per well in a 24-well plate, 1 day before
co-culture. PBMCs were harvested and co-cultured
with PICs in RPMI medium as follows; no PBMCS, 1:10,
1:20, and 1:40. After 4 h of co-culture, PBMCs were
discarded; PICs were harvested and subsequently
labelled with anti-CD45 antibody/Annexin V-PE
Apoptosis Detection Kit I (BD Biosciences) and
analyzed by ﬂow cytometry using a FACSCanto II and
FACS DIVA V8.0.1 software (BD Biosciences).
STATISTICAL ANALYSIS. Data are reported asmean
SD. Signiﬁcance between 2 groups was determined by
paired samples Student’s t-test and in multiple com-
parisons by analysis of variance. Holm-Sídák method
was used to locate the differences. A probability of<5%
(p<0.05) was considered to be statistically signiﬁcant.
Data were analyzed using SPSS Statistics version 22
software (IBM, Armonk, New York).
RESULTS
CTX-INDUCED INJURY IS A REPRODUCIBLE MODEL
OF PORCINE SKELETAL MUSCLE DAMAGE. In order
to determine a robust model to investigate allogeneic
pPIC regenerative therapy in vivo, 2 different models
of porcine skeletal muscle damage were ﬁrst evalu-
ated. Freeze/crush and CTX injuries were assessed
because they have been extensively used to model
skeletal muscle damage in small animals (28). The
freeze/crush injury is a segmental model of trauma,
selectively affecting muscle ﬁbers and interstitial
tissue without disrupting the main innervation of the
tissue. The CTX injury, induced using a series of CTX
injections, is a diffuse injury model. All animals
recovered from the surgical procedure without com-
plications and were fully ambulatory within a few
hours after surgery with only minor swelling
observed at the surgical site. Histological assessment
of explanted muscle revealed that the freeze/crush
injury, as expected, was restricted to the superﬁcial
layer of muscle adjacent to a deep uninjured region
(Supplemental Figure S1). CTX-injured muscles
showed a diffuse pattern of damage throughout
the tissue (Supplemental Figure S1). Both injuries
resulted in signiﬁcantly decreased muscle ﬁber CSA
(CTX-injured 53  7% per total area (p < 0.0001);
freeze/crush-injured 66  7% per total area
(p ¼ 0.0015), compared with uninjured contralateral
control muscle (83  4% per total area) (Supplemental
Figure S1). Moreover, CTX-injured muscle exhibited a
signiﬁcant (p < 0.018) reduction in muscle ﬁber CSA,
compared with freeze/crush-injured muscle
(Supplemental Figure S1), showing that CTX injurydamaged a greater number of myoﬁbers. There was
also a signiﬁcant (p < 0.01) increase in the abundance
of connective tissue in both injury models
(Supplemental Figure S1). Both injuries resulted in an
overall reduction in muscle ﬁber diameter, with CTX
injury showing the greatest reduction (37.9  8.5 mm),
which was statistically signiﬁcant (p < 0.0001),
compared with uninjured control (63.3  15.7 mm)
(Supplemental Figure S1).
A decreased myoﬁber diameter implies the occur-
rence of small, newly formed, regenerating myo-
ﬁbers. Therefore, centralized nuclei, a marker of
newly regenerated ﬁbers, were evident in both in-
juries however they were more prevalent in the
freeze/crush-injured muscle (27.27  11.34 per 100
myoﬁbers; p < 0.0001), compared with CTX-injured
muscle (10.8  6.0 per 100 myoﬁbers) and uninjured
CTRL (Supplemental Figure S1), suggesting that
freeze/crush-injured muscles were more advanced in
the regeneration process at 14 days post-injury,
compared with CTX-injured muscles. Immunohisto-
chemical staining of injured muscle was performed to
determine the extent of regeneration with respect to
early myosin isoforms. nMHC staining was observed
in both larger ﬁbers and small angular myoﬁbers of
CTX- and freeze/crush-injured muscle at 14 days
post-injury (Supplemental Figure S1), and in the
freeze/crush injury, nMHC expressing myoﬁbers were
restricted to the uppermost superﬁcial layer of the
muscle. The CTX-injured muscles showed a diffuse
pattern of nMHC expression, and nMHCpos myoﬁbers
were more prevalent in CTX-injured muscle (37.2 
5.7%) compared with freeze/crush-injured muscle
(25.6  5.3%). nMHCpos ﬁbers were also smaller in
CTX-injured muscle (21.7  4.9 mm) compared with
those identiﬁed in the freeze/crush-injured muscle
(24.8  5.3 mm), supporting our observation that
freeze/crush injury regeneration is more advanced at
14 days compared with CTX injury, which induces
widespread injury with incomplete regeneration at
14 days (Supplemental Figure S1).
These results conﬁrmed that CTX injury is a repro-
ducible and diffuse injury model for testing skeletal
muscle regeneration in the pig. However, in order to
conﬁrmwhether 14 dayswas an appropriate time point
for studying porcine skeletal muscle regeneration, a
subset of animals were also sacriﬁced 21 days post-CTX
injury. Immunohistochemical staining of muscle cross
sections revealed that at 21 days, while there was a
signiﬁcant difference between the muscle ﬁber CSA
(75  3% muscle ﬁber per total area), compared with
uninjured control (82  3% muscle ﬁber per total area)
(p ¼ 0.0027), this was largely reduced compared to
14 days post-injury (Supplemental Figure S2). These
Lewis et al. J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 2 , N O . 6 , 2 0 1 7
Allogeneic pPICs Enhance Repair of Injured Muscle D E C E M B E R 2 0 1 7 : 7 1 7 – 3 6
724ﬁndings suggest that 21 days after CTX injury the
muscle has undergone almost complete regeneration.
Therefore, to measure whether allogeneic pPIC trans-
plantation could enhance the regeneration of skeletal
muscle, CTX was selected as the injury model with
sacriﬁce of the pigs at 14 days post-injury.
TRANSPLANTATION OF ALLOGENEIC GFPpos pPICs
IMPROVES SKELETAL MUSCLE ARCHITECTURE AND
ACCELERATES MYOFIBER REGENERATION. pPICs,
which have previously been phenotyped and propa-
gated over long term culture maintaining phenotypic
and genomic stability (16), were transduced with a
lentiviral vector encoding a GFP reporter. A total of
87.2% of pPICs were GFP-positive (GFPpPICs) as
determined by ﬂow cytometry (Supplemental
Figure S3). GFPpPICs were propagated over 9 pas-
sages (P3 to P12) to generate the required number of
cells for transplantation (20  106 per animal).
GFPpPICs maintained a PIC phenotype after GFP
transduction, which was stable up to P12, remaining
positive for PW1 and CD34, and negative for CD45 and
Pax7 (Supplemental Figure S3). Furthermore,
GFPpPICs at P12 were comparable in their gene
expression proﬁle and bipotent differentiation po-
tential to unlabeled pPICs (Supplemental Figure S3).
Initial histological observations indicated that
pPIC-treated muscle had signiﬁcantly improved
muscle architecture and increased BrdUpos central-
ized myonuclei, indicative of undergoing accelerated
regeneration, compared with CTX-PBS–treated mus-
cle (Figures 1A and 1B). There was a signiﬁcant
(p < 0.001) increase in muscle ﬁber CSA in pPIC-
treated muscle (78  5% per total area), compared
with CTX-PBS (62  2% per total area) (Figure 1C), and
the ratio of muscle ﬁber to connective tissue CSA of
pPIC-treated muscle (78% : 22  5% per total area) at
14 days was closer to uninjured contralateral control
muscle (87% : 13  3% per total area) (Figure 1C).
Immunohistochemistry revealed a marked increase
(p ¼ 0.0012) in the number of centralized, BrdUpos
myoﬁber nuclei, which indicates newly regenerated
ﬁbers, in pPIC-treated muscles (15  3%/total myo-
ﬁbers), compared with CTX-PBS–treated muscles
(2  1%/total myoﬁbers) (Figures 1B and 1D). The un-
injured contralateral control muscle had a very low
number of BrdUpos nuclei and centralized nuclei,
indicating the low turnover of skeletal myoﬁbers in
uninjured, resting muscle (0.04  0.08%) (Figures 1B
and 1D). The diameter of the BrdUpos regenerating
myoﬁbers in pPIC-treated muscles were found to be
signiﬁcantly larger (p < 0.0001) (41.4  10 mm) than
those of CTX-PBS–treated muscles (23.8  7.3 mm)14 days post-injury (Figure 1E). Taken together, these
ﬁndings support an improved and accelerated
regeneration of injured skeletal muscle, following
transplantation of allogeneic pPICs.
ALLOGENEIC pPICs STIMULATE NEOANGIOGENESIS
WHEN TRANSPLANTED INTO INJURED PORCINE
SKELETAL MUSCLE. Immunohistochemical staining
revealed a signiﬁcant (p < 0.0001) increase in capil-
lary density with CTX-pPIC treatment, compared with
CTX-PBS and uninjured muscle (Figures 2A and 2B).
Moreover, the presence of BrdUpos/vWFpos capillaries
in the pPIC-treated muscle conﬁrmed their formation
post-injury and pPIC transplantation (Figure 2C).
Quantiﬁcation revealed a signiﬁcant (p < 0.0001) in-
crease in the number of BrdUpos/vWFpos capillaries in
pPIC-treated skeletal muscle (94  3% per total cap-
illaries), compared with CTX-PBS–treated (56  3%
per total capillaries) skeletal muscle (Figure 2D).
These ﬁndings show that allogeneic pPIC therapy
stimulated angiogenesis in the injured skeletal
muscle.
ALLOGENEIC pPIC TRANSPLANTATION ACTIVATES
ENDOGENOUS PICs. To determine whether GFPpPIC
transplantation had stimulated the activation of
endogenous progenitor cells, sections were stained
for PW1, Pax7, and GFP. We found a signiﬁcant
(p ¼ 0.0145) increase in the number of endogenous
PW1pos/Pax7neg/GFPneg PICs in skeletal muscle that
had been treated with allogeneic GFPpPICs (7.9 
1.9%/total nuclei), compared with CTX-PBS–treated
CTRL (4.6  0.5%/total nuclei) (Figures 3A and 3B). We
also quantiﬁed the number of PW1pos/Pax7pos/GFPneg
satellite cells and found that pPIC treatment did not
signiﬁcantly alter the number of satellite cells (2.6 
0.4%/total nuclei), compared with CTX-PBS treat-
ment (2.4  0.5%/total nuclei) (Figures 3C and 3D).
These data show that at 14 days post-injury, alloge-
neic pPIC transplantation had a stimulatory effect on
the endogenous pPICs population, resulting in an
increase in their number.
ALLOGENEIC GFPpos pPICs ARE CLEARED BY THE
HOST’S IMMUNE SYSTEM. To determine whether
allogeneic GFPpPICs had persisted in the skeletal
muscle and directly contributed to the regeneration, or
as expected, had been cleared by the host’s immune
system, skeletal muscle cross sections were costained
for GFP and laminin. Only a few GFPpPICs (1 GFPpos
nuclei/1,560 counted) persisted within the skeletal
muscle 14 days post-injury (Figures 4A and 4B). More-
over, we found that the very few donor GFPpPICs
that had remained had taken up residence within
the interstitial spaces and maintained expression of
FIGURE 1 Transplantation of GFPpos Allogeneic pPICs Accelerates Skeletal Muscle Regeneration
(A) HVG staining of uninjured CTRL, CTX-PBS– and CTX-pPIC–treated muscle showing improved skeletal muscle architecture in pPIC-treated
muscle, scale bar ¼ 100 mm. Insets show 40 magniﬁcation, scale bar ¼ 50 mm. (B) Immunohistochemical staining indicates an increase in
BrdUpos centralized nuclei in CTX-pPIC–treated muscle compared with uninjured CTRL and CTX-PBS–treated muscle, scale bar 50 ¼ mm.
(C) Quantiﬁcation of the ratio of skeletal muscle to connective tissue CSA in uninjured CTRL, CTX-PBS–, and CTX-pPIC–treated muscle
determined from 5 ﬁelds of view per muscle, n ¼ 5 animals per group. Data are mean  SD, *p < 0.01 versus uninjured CTRL, **p < 0.001
versus CTX-pPIC–treated muscle. (D) BrdUpos centralized nuclei per total myoﬁbers, determined from 5 ﬁelds of view per muscle, n ¼ 5
animals per group. Data are mean  SD, *p < 0.0001 versus uninjured CTRL, **p ¼ 0.0012 versus CTX-PBS–treated. (E) Average myoﬁber
diameter of regenerating (BrdUpos centralized nuclei) myoﬁbers determined from 5 ﬁelds of view per muscle, n ¼ 5 animals per group. Data
are mean  SD, *p < 0.0001 versus CTX-PBS–treated. CSA ¼ cross sectional area; CTRL ¼ control; CTX ¼ cardiotoxin; HVG ¼ hematoxylin
and van Gieson; PBS ¼ phosphate buffered saline; pPIC ¼ porcine PW1pos/Pax7neg interstitial cell.
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725PW1. No GFPpos nuclei were identiﬁed beneath the
basal lamina in a satellite cell position (Figure 4A,
Supplemental Figure S4). We found only a rare occur-
rence of a single GFPpos myoﬁber (per 1,000 myoﬁbers
counted) (Figures 4A and 4B). At 14 days post-injury, no
GFPpPICs were identiﬁed in other tissues (lung,
spleen, or liver) or in the uninjured contralateral
control muscle (Supplemental Figure S4).
Muscle sections were stained for the inﬁltration of
cytotoxic T cells, cytotoxic T cells/natural killercells (NK), and macrophages expressing CD8a, Gran-
zyme B, and IBA-1, respectively (Supplemental
Figure S5). CD8apos (p ¼ 0.0008) and Granzyme Bpos
(p < 0.0001) cells were signiﬁcantly up-regulated in
CTX-pPIC–treated muscle, compared with CTX-PBS
and uninjured muscle (Figures 4C and 4D). In terms
of the innate immune cells, IBA-1-positive macro-
phages inﬁltration was signiﬁcantly increased
(p < 0.0004) in both CTX-PBS– and CTX-pPIC–treated
muscle relative to uninjured muscle (Figure 4E).
FIGURE 2 Allogeneic GFPpos pPICs Stimulate Neoangiogenesis Following Transplantation Into Injured Skeletal Muscle
(A) Skeletal muscle cross sections were stained for vWF to evaluate capillary density, scale bar ¼ 50 mm. (B) Number of capillaries per myoﬁber, determined from
5 ﬁelds of view per muscle, n ¼ 5 animals per group. Data are mean  SD, *p < 0.0001 versus uninjured. (C) Newly formed BrdUpos/vWFpos capillaries were identiﬁed
14 days post-injury, scale bar ¼ 20 mm. (D) Percentage of BrdUpos capillaries per total capillaries, determined from 5 ﬁelds of view per muscle, n ¼ 5 animals per group.
Data are mean  SD, *p < 0.0001 versus CTX-PBS–treated. vWF ¼ Von Willebrand factor; other abbreviations as in Figure 1.
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726To document that the immune cells (cytotoxic
T cells/NK cells) were responsible for clearance of
pPICs, we performed cytotoxicity assays with porcine
PBMCs in vitro. Porcine PHA-activated and -inacti-
vated PBMCs were co-cultured with pPICs at several
seeding densities, and apoptosis (Annexin V/7-AAD)
of pPICs was measured by ﬂow cytometry. Activated
PBMCs induced signiﬁcant (p < 0.0001) apoptosis,
between 70% and 80% in pPICs (Figure 4F). Apoptosis
of pPICs did not occur when inactive PMBCs were
co-cultured with pPICs (Figure 4G).
Taken together, these data suggest that allogeneic
pPICs exert their action via a paracrine effect, acti-
vating endogenous progenitors before being cleared
by the host immune system post-injury.
ALLOGENEIC pPICs EXPRESS AN ARRAY OF
PRO-REGENERATIVE PARACRINE FACTORS. To
identify the mechanism through which pPICs wereable to promote regeneration in skeletal muscle, we
looked to their secretome. Porcine PICs were found to
express a range of cytoprotective/proregenerative
growth factors and cytokines (Figure 5A), similar to
that observed for stem/progenitor cells, such as
mesenchymal stem cells (29) and satellite cells (30).
In particular, we noted the greatest relative expres-
sion (>10,000) was chemokine (C-C Motif) ligand 2
(CCL2), monocyte chemotactic and activating factor,
which is considered to be essential for stimulating
muscle repair (31,32) (Figure 5A). Tissue inhibitor of
metalloproteinases (TIMP)-1 and -2, involved in tissue
remodeling, were also highly expressed (>100 rela-
tive expression) (Figure 5A). Factors that were 10 to
100 relative expression included those implicated in
the activation, migration, proliferation, and differ-
entiation of muscle stem/progenitor cells, such as
periostin, NRG-1/2, TGF-bs, FGFs, HGF, IGF-1, INHBA,
LIF, IL-6, and SCF (33–42) (Figure 5A). Interestingly,
FIGURE 3 Allogeneic GFPpos pPICs Stimulate Endogenous pPIC Activation
(A) Representative image of GFPneg/PW1pos/Pax7neg pPICs resident in CTX-pPIC–treated skeletal muscle 14 days post-injury, scale bar ¼ 50 mm. (B) Number of
GFPneg/PW1pos/Pax7neg pPICs per total nuclei, determined from 3 ﬁelds of view per muscle, n ¼ 5 animals per group. Data are mean  SD, *p ¼ 0.0145 versus
CTX-PBS–treated. (C) GFPneg/PW1pos/Pax7pos satellite cells per total nuclei, determined from 3 ﬁelds of view per muscle, n ¼ 5 animals per group. Data are mean  SD.
(D) Representative image of PW1pos/Pax7pos satellite cells resident in both CTX-PBS– and CTX-pPIC–treated skeletal muscle 14 days post-injury, scale bar ¼ 50 mm.
Abbreviations as in Figure 1.
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727GDF-11, which has been shown to ameliorate the age-
related dysfunction of skeletal muscle by rescuing the
function of aged muscle stem cells (43), was signiﬁ-
cantly expressed by pPICs (Figure 5A). Proangiogenic
factors including VEGFa, PDGFs, and IL-8, capable of
stimulating recruitment of endothelial cells and
initiating vascularization following injury (44–46),
were also found to be highly expressed (>10) in pPICs
(Figure 5A).
To enrich for a highly paracrine secreting pPIC
population, we identiﬁed whether pPICs expressed
differential levels of factors depending on their dif-
ferentiation status. This was necessary because
following pPIC transplantation into injured skeletal
muscle, the microenvironment could facilitate pPICs
to differentiate into a myogenic precursor-like celltype, which could then express differential levels of
proregenerative factors, compared with its undiffer-
entiated counterpart. Therefore, a comparative
qRT-PCR analysis was performed between undiffer-
entiated pPICs and those that had undergone 24 h of
myogenic differentiation in vitro (differentiated
pPICs). Overall, there were distinct differences be-
tween the differentiated and undifferentiated pPICs
(Figures 5B and 5C, Supplemental Table S1).
Volcano plot analysis highlighted factors that were
signiﬁcantly (>2-fold) down- or up-regulated in
differentiated compared with undifferentiated pPICs
(Figure 5C, Supplemental Table S1). Cytokines and
growth factors involved in stem cell migration and
proliferation, such as HGF (9), were up-regulated in
undifferentiated pPICs. Whereas an up-regulation of
FIGURE 4 Allogeneic GFPpos pPICs Are Cleared by the Host Immune System
(A) Immunohistochemistry identiﬁed a small number of donor GFPpos pPICs at 14 days post-transplantation, scale bar ¼ 100 mm. GFPpos cells were found as nuclei
within the interstitial spaces between the muscle ﬁbers (bottom inset), and a rare GFPpos muscle ﬁber was also identiﬁed (top inset). (B) Quantiﬁcation of GFPpos cells
to total number of nuclei or myoﬁbers in parafﬁn embedded skeletal muscle cross sections, n ¼ 5. Data are mean  SD, *p ¼ 0.001 versus CTX-PBS–treated. (C)
Quantiﬁcation of CD8pos cells per total nuclei (%) determined from 5 ﬁelds of view per group. Data are mean  SD, *p ¼ 0.0008 versus uninjured muscle,
**p ¼ 0.0008 versus CTX-PBS–treated. (D) Quantiﬁcation of Granzyme Bpos cells per total nuclei (%) determined from 5 ﬁelds of view per group. Data are mean 
SD, *p < 0.0001 versus uninjured muscle, **p < 0.0001 versus CTX-PBS–treated. (E) Quantiﬁcation of IBA-1pos cells per total nuclei (%) determined from 5 ﬁelds of
view per group. Data are mean  SD, *p ¼ 0.0004 versus uninjured muscle. Porcine PICs were co-cultured with either (F) PHA-activated porcine PBMCs or (G)
inactivated porcine PBMCs at different ratios and analyzed for apoptosis using Annexin V/7-AAD staining and ﬂow cytometry. Early apoptosis of CD45neg PICs is
represented by Annexin V expression, whereas late apoptosis is represented by double-positive Annexin V/7-AAD staining, determined from duplicate wells per
group. Data are mean  SD, *p < 0.0001 versus pPICs only. PBMC ¼ peripheral blood mononuclear cell; other abbreviations as in Figure 1.
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728factors involved in stem/progenitor activation and
differentiation, such as INHBA, SPP-1, IL-8, BMP4,
IGF-1, NRG-1, and periostin, were expressed in
differentiated pPICs (Figure 5C). We conﬁrmed
changes in expression at the protein level of undif-
ferentiated compared with differentiated pPICS for a
selected panel of up- or down-regulated factors,
which supported the transcript data (Figure 5D).
These data suggest that both undifferentiated and
differentiated pPICs could be used to exert a pro-
regenerative paracrine effect, but differentiated
pPICs up-regulate expression of a vaster array of
proregenerative factors.THE pPIC SECRETOME PROMOTES A REGENERATIVE
RESPONSE IN VITRO. We next examined the effect
of the pPIC secretome on human myoblast and pPIC
proliferation and differentiation in vitro. CM signiﬁ-
cantly (p < 0.0001) increased proliferation of pPICs
(Figure 6A) and myoblasts (Figure 6B), compared with
UM and ICM where the secreted factors were absent
or denatured, respectively (Figures 6A and 6B). Next,
we showed that factors that were expressed by pPICs,
such as IGF-1, HGF, and NRG-1, when supplemented
to pPICs in vitro, signiﬁcantly (p < 0.0001) increased
their proliferation (Figure 6C), and for TGF-b1,
increased pPIC differentiation (Figures 6D and 6E)
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729assessed by quantifying the fusion index of MHCpos
cells, compared with unsupplemented control. More-
over, in vitro angiogenesis assays conﬁrmed that
secreted factors in CM promoted HUVECs to form
endothelial networks, evidenced by a signiﬁcant in-
crease in capillary area (p ¼ 0.0189) and total tube
length (p ¼ 0.0224) compared with ICM (Figures 6F and
6G, Supplemental Figure S5). Taken together, these
data demonstrate that factors secreted by pPICs pro-
mote proliferation and differentiation of skeletal mus-
cle progenitors and stimulate angiogenesis in vitro.
ADMINISTRATION OF HGF AND IGF-1 IMPROVES
SKELETAL MUSCLE REGENERATION, BUT NOT TO
THE SAME EXTENT AS pPIC TRANSPLANTATION. To
determine whether cytokines produced by other cell
types other than pPICs could contribute to repair, we
immunostained muscle sections for 4 growth factors,
IGF-1, HGF, TGF-b1, and NRG1. CTX-pPIC–treated
transplanted muscle showed increased expression of
all factors, compared with CTX-PBS–treated and un-
injured muscle. Speciﬁcally, HGF expression was
mainly conﬁned to the myoﬁbers; IGF-1 and NRG1
expression was conﬁned to the myoﬁbers and inter-
stitial cells, and TGFb1 expression was conﬁned to the
interstitial cells, following CTX-pPIC–treated trans-
plantation (Supplemental Figure S7).
To determinewhether IGF-1 andHGF could improve
regeneration to a similar degree as pPIC trans-
plantation, we injected IGF-1 and HGF into CTX-
injured skeletal muscle, and we also administered
the same growth factors through a UPy hydrogel, as we
have done previously in the porcine chronic MI model
(47). We found that IGF-1/HGF administration
improvedmuscle regeneration, increasing the number
of BrdUpos myoﬁbers (8  2%/total myoﬁbers vs. 2 
1%/total myoﬁbers CTX-PBS–treated) and the BrdUpos
regenerating myoﬁbers were larger (33.28  6.3 mm vs.
23.8  7.3 mm CTX-PBS–treated) (Figure 7). However,
these effects were not further enhanced if the growth
factors were administered through the UPy hydrogel
(BrdUpos myoﬁber 8  3%/total myoﬁbers and BrdUpos
regeneratingmyoﬁbers diameter 35.584.98 mm), and
more importantly, the improvements were not as great
as transplantation of pPICs (Figure 1). Therefore, pPICs
are superior to targeted growth factor administration
because they release a plethora of growth factors and
cytokines, which activate multiple endogenous repair
mechanisms, contributing to accelerated and effective
repair and regeneration in vivo.
DISCUSSION
The present study documents that in a porcine model
of skeletal muscle damage, which is applicable tohumans, transplantation of allogeneic pPICs persist
long enough to elicit a paracrine effect by secretion of
regenerative cytokines and growth factors. These
factors stimulate endogenous progenitor cell activa-
tion and differentiation, leading to accelerated and
improved autologous myoﬁber regeneration and
microvessel formation.
Skeletal muscle, although capable of undergoing
extensive regeneration, exhibits diminished regen-
erative capacity in ageing and disease. The loss of
regenerative capacity is largely thought to be due to
intrinsic and extrinsic changes that ultimately abro-
gate resident progenitor cell competence (48,49).
Intrinsic mechanisms include epigenetic changes,
telomere attrition, DNA damage or mitochondrial
dysfunction. Extrinsic changes are associated with
alterations of the muscle progenitor cell niche, which
can be inﬂuenced by both systemic circulating factors
and local changes associated with ageing, disease or
metabolic pathways, which can negatively impact
endogenous progenitor cells.
To date, most attempts to regenerate skeletal
muscle have focused on delivery of culture-expanded
myoblasts (50) or CD133pos cells (51), which have been
shown to engraft and generate functional satellite
cells after xenotransplantation in rodent models,
suggesting the potential for autologous regenerative
applications. Despite advances, the results of clinical
trials (52,53) collectively show low engraftment efﬁ-
ciency with prevailing issues associated with immune
rejection. Over recent years, a large number of reports
have shown that transplanted stem cells mediate
their beneﬁcial effects via several indirect mecha-
nisms, such as recruitment of endogenous progenitor
cells, induction of angiogenesis, protection of exist-
ing survived cells and reduction in ﬁbrosis and
inﬂammation (9,54). These processes are regulated
by a variety of small molecules, proteins, mRNAs/
miRNAs, and paracrine factors produced by the
adoptively transferred stem cells in the damaged
tissue milieu (54–56). This concept has been prevalent
for many years, where it was shown the infusion of
human umbilical cord blood cells can aid in stroke
recovery due to enhanced angiogenesis, which may
have induced neuroblast migration to the site of
injury (57). Moreover, transplanted macrophages can
promote liver repair by activating hepatic progenitor
cells (58). We have previously documented the pro-
tective and regenerative effects of allogeneic CSCs
transplantation or growth factor administration in
porcine models of MI (9,12). CSCs express high levels
of numerous cytokines, including chemokines
(TCA-3, SDF-1, 6Ckine), vascular growth factors
(VEGF, EPO, bFGF, SCF), survival and activation
FIGURE 5 Allogeneic pPICs Express an Array of Proregenerative Paracrine Factors
Continued on the next page
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731factors (IGF-1, HGF, PDGFs), and cardiac differentia-
tion factors (Activin A, Dkk-1, TGF-b), which are
released at the site of injury, activating endogenous
repair mechanisms and improving cardiac function
(9,12,59,60).
To our knowledge, this is the ﬁrst study to show
that allogeneic stem/progenitor cell transplantation
elicits a paracrine effect by activating endogenous
repair processes to improve and accelerate muscle
regeneration in the pig. To date preclinical studies
have not addressed the magnitude of the regenera-
tion required to target whole skeletal muscle regen-
eration in the clinic. The best published results report
regeneration in the region of milligrams of skeletal
muscle in small mouse animal models, whereas
humans would likely require at least a 3-fold increase
in muscle mass in comparison (61). Here, we devel-
oped a large animal, preclinical skeletal muscle injury
model, which is easily reproducible and is a useful,
clinically applicable model to assess the effects of
proof-of-concept regenerative therapies designed to
regenerate large volumes of muscle. The animals that
were used were juvenile animals,w2-month-old pigs,
which were selected due to their reduced size and
practicability issues. They also had a functioning
immune system required to test our theory that
transplanted pPICs would be cleared by the host im-
mune system. We showed that transplanted pPICs
were cleared from the host by 14 days post-
transplantation, and activated porcine PMBCs effec-
tively killed pPICs in a cytotoxicity assay in vitro.
Analysis of the immune response revealed that CTX-
pPIC–treated muscle had increased CD8a (adaptive
immunity) and Granzyme B (adaptive/innate immu-
nity) cells and both CTX-PBS– and CTX-pPIC–treated
muscle had comparable inﬁltration of macrophages
that were signiﬁcantly greater than in uninjured
muscle. On the basis of these results, we propose that
the donor pPICs were removed in the early phases
of regeneration, and the increased regenerativeFIGURE 5 Continued
(A) Expression proﬁle of pPICs arrayed by quantitative reverse transcrip
expression of 5 housekeeping genes ACTB, B2M, GAPDH, HPRT1, and RPL
differentially regulated pPIC transcripts. The colors in ascending order fr
measured average difference values. The tree on the left of the clusterg
clustered expression patterns, n ¼ 3 for both undifferentiated and differe
differentially regulated by at least 2-fold were selected and are illustrat
up-regulated, black represents genes whose expression levels did not c
differentiated pPICs compared with undifferentiated pPICs, n ¼ 3. (D)We
environment led to an increase in IGF-1, TGF-b1, and NRG-1, and a decr
pPIC ¼ porcine PW1pos/Pax7neg interstitial cell; Undiff ¼ undifferentiateresponse was mediated as a consequence of the
activated endogenous progenitors.
Transplantation of allogeneic pPICs was found to
stimulate the endogenous repair mechanisms of this
tissue, leading to improved and accelerated skeletal
muscle regeneration, with increased muscle CSA, an
increased number of BrdUpos centralized nuclei, and
larger regenerating myoﬁbers compared with
CTX-PBS-treated muscle. In addition to myoﬁber
regeneration following muscle trauma, damaged
blood vessels lead to tissue hypoxia at the injury site
(62); therefore, new capillary formation after injury is
also necessary for functional muscle recovery (63).
Secretion of angiogenic factors, such as VEGF, at
the injury site is an important mediator of this pro-
cess, and several studies have shown that VEGF
improves skeletal muscle repair by promoting
angiogenesis (44,64). This study identiﬁed that
following allogeneic pPIC transplantation, there was a
signiﬁcant increase in new capillary formation,
which would have contributed to the improvement in
muscle regeneration observed.
Allogeneic pPIC treatment was shown to activate
and increase the number of endogenous PW1pos/
Pax7neg PICs, yet a similar increase in number was not
found for PW1pos/Pax7pos satellite cells. Therefore,
pPICs may either have a greater stimulatory effect on
the endogenous PICs, or more likely, the time point of
14 days is insufﬁcient to accurately measure the effect
of pPIC transplantation on satellite cell activation.
Because satellite cells are the main contributor to
muscle regeneration (65), it is likely that the satellite
cells became activated early (days 1 to 3) and had
returned to normal, quiescent levels once the regen-
eration process was almost complete at 14 days.
Moreover, the assessment of satellite cell activation is
hampered by lack of markers to identify activated
satellite cells in the interstitial space (30). Also, the
endogenous PICs might have maintained an activated
state for longer due to their role in vascular repair.tion polymerase chain reaction, relative expression to average
13A. Data represent mean  SD, n ¼ 3. (B) Hierarchical clustering of
om green to red represent the magnitude of gene expression for the
ram indicates the pairwise similarity relationships between the
ntiated pPICs (24 h in differentiation medium). (C) Genes that were
ed in a volcano plot. Red indicates those genes that were
hange, whereas green indicates genes that were down-regulated in
stern blots conﬁrmed that pPIC exposure to a myogenic permissive
ease in HGF protein expression, n ¼ 3. Diff ¼ differentiated;
d.
FIGURE 6 The pPIC Secretome Promotes a Regenerative Response in Vitro
(A) Quantiﬁcation of pPIC BrdU 24-h proliferation assay in standard growth media (GM), 24-h pPIC conditioned media (CM), unconditioned media (UM), or heat-
inactivated conditioned media (ICM). Total BrdUpos cells per total nuclei, determined from 5 ﬁelds of view per group. Data are mean  SD, *p < 0.0001 versus all
conditions. (B) Quantiﬁcation of human myoblasts BrdU 24-h proliferation assay in GM, CM, UM, or ICM. Total BrdUpos cells per total nuclei, determined from 5 ﬁelds of
view per group. Data are mean  SD, *p < 0.0001 versus UM and ICM. (C) Quantiﬁcation of BrdU 24-h proliferation assay in medium supplemented with IGF-1, HGF,
TGF-b1, or NRG-1 compared with control. Total BrdUpos cells per total nuclei, determined from 5 ﬁelds of view per group. Data are mean  SD, *p < 0.0001 versus
control and TGF-b1. (D) Representative micrographs of pPIC immunocytochemical staining for MHC after 5 days of myogenic differentiation in the presence of IGF-1,
HGF, NRG-1, or TGF-b1 compared with control. (E) Quantiﬁcation of pPIC fusion index after 5 days of myogenic differentiation in the presence of IGF-1, HGF, TGF-b1, or
NRG-1 compared with control. Data are mean  SD, *p < 0.0001 versus control for >3 nuclei. (F and G) Endothelial network formation quantiﬁed as capillary area (F)
and total length of capillaries (G), after human umbilical vein endothelial cells were exposed to endothelial GM, CM, UM, and ICM. Data are mean  SD, *p < 0.05
versus ICM and GM. MHC ¼ myosin heavy chain; other abbreviations as in Figure 1.
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732However, these data suggest the existence of a feed-
back loop triggered by the transplanted pPICs that
activates the production of growth and survival fac-
tors by the endogenous PICs, which could explain
their persistence and longer duration of activation
over 14 days. The relationship between satellite cells
and endogenous PICs during the repair and regener-
ation of skeletal muscle thus warrants further
investigation.We determined whether the paracrine effect of
pPICs depended on their differentiation status, and
predicted that upon transplantation, the in vivo
microenvironment encountered by the pPICs during
the ﬁrst 24 h would promote pPIC differentiation. The
secretome of 24-h differentiated pPICs showed
increased expression of factors, such as IGF-1, NRG-1,
and TGF-b1 and periostin, which facilitated prolifer-
ation and differentiation of endogenous muscle stem/
FIGURE 7 Administration of IGF-1/HGF and UPy IGF-1/HGF Stimulates Moderate Skeletal Muscle Regeneration
(A) HVG staining of uninjured, CTX:IGF-1/HGF–, and CTX:UPy IGF-1/HGF–treated muscle, scale bar ¼ 100 mm. (B) Immunohistochemical
staining shows a number of BrdUpos centralized nuclei in both CTX:IGF-1/HGF– and CTX:UPy IGF-1/HGF–treated muscle compared with
uninjured muscle, scale bar ¼ 50 mm. (C) Quantiﬁcation of the ratio of skeletal muscle to connective tissue CSA in uninjured, CTX:IGF-1/HGF–,
and CTX:UPy IGF-1/HGF–treated muscle determined from 5 ﬁelds of view per muscle, n ¼ 5 animals per group. Data are mean  SD, *p <
0.01 versus uninjured CTRL. (D) BrdUpos centralized nuclei per total myoﬁbers, determined from ﬁve ﬁelds of view per muscle, n ¼ 5 animals
per group. Data are mean  SD, *p < 0.001 versus uninjured CTRL. (E) Average myoﬁber diameter of regenerating (BrdUpos centralized
nuclei) myoﬁbers determined from 5 ﬁelds of view per muscle, n ¼ 5 animals per group. Data are mean  SD, *p < 0.0001 versus uninjured
CTRL. Abbreviations as in Figure 1.
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733progenitor cells. In vitro assays conﬁrmed that
conditioned media containing these secreted factors
stimulated the proliferation of both pPICs and human
myoblasts, and stimulated endothelial network for-
mation of HUVECs. Moreover, IGF-1, HGF, and NRG-1,
when supplemented individually to the culture me-
dia, stimulated the proliferation of pPICs, whereasTGF-b1 was shown to play a role in promoting pPIC
myogenic differentiation. Therefore, allogeneic pPIC
transplantation elicits a paracrine effect on endoge-
nous progenitor cells, increasing and accelerating
skeletal muscle regeneration.
Many different stem/progenitor cells (66–72) have
been investigated for cellular therapy, each with their
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Allogeneic PIC transplantation elicits a paracrine
effect through secretion of regenerative cytokines and
growth factors, which stimulate endogenous progen-
itor cell activation and differentiation, leading to
accelerated and improved myoﬁber regeneration and
microvessel formation. Shortly after they have elicited
their paracrine effect, they are removed by the host
immune system. This allogeneic cell approach is
considered an off-the-shelf, cost-effective, easy-to-
apply, and readily-available regenerative therapeutic
strategy.
TRANSLATIONAL OUTLOOK: This study provides
a proof-of-concept for an allogeneic cell therapy
approach, which with further experimental develop-
ment and reﬁnement may lead to an effective, simple,
clinically applicable, and widely available strategy for
repair of the heart and other organs.
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Given the striated muscle similarities between skel-
etal and cardiac muscle, skeletal muscle–derived
myoblasts were the ﬁrst cell type to enter the clinical
arena of heart repair (73). Skeletal muscle–derived
progenitors showed promise in that they were
proangiogenic and relatively resistant to hypoxic
conditions, and therefore improved functional out-
comes upon transplantation (74,75). However, due to
issues associated with limited expansion in vitro and
arrhythmogenic complications in vivo (76), they are
widely considered unsuitable for cardiac regenera-
tion. Utilizing PICs as a source of stem/progenitor
cells for allogeneic cell therapy overcomes several of
the limitations encountered with other adult muscle
progenitor therapies and mesenchymal allogeneic
therapies. Indeed, harvesting of PICs from an easily
accessible source, such as skeletal muscle, means a
simple muscle biopsy would be performed, and with
an unlimited proliferative capacity in vitro, a large
number can be propagated, maintaining a stable
phenotype and genotype over passage number (16).
Together with a rich secretome of regenerative fac-
tors, these properties make PICs an ideal candidate
cell source for the repair of the heart as well as other
tissues.
STUDY LIMITATIONS. One of the main limitations
associated with the clinical application of stem cell–
based therapies is the time and costs associated with
generating the large number of clinical grade cells
required for treatment. Therefore, it may be beneﬁ-
cial to assess the effect of different doses of pPICs to
ascertain whether fewer cells could stimulate the
same effect. Nevertheless, we envision the main
advancement of these ﬁndings to be in identifying
speciﬁc factors responsible for eliciting accelerated
and improved muscle and microvessel regeneration.
This would enable us to develop cell-free therapies
that match or exceed the level of regeneration re-
ported here, which would greatly facilitate clinical
application. However, the delivery of HGF and IGF-1
to the injured skeletal muscle did not result in
equivalent levels of muscle regeneration documented
for pPIC transplantation. Therefore, delivery of a
multitude of factors/molecules is necessary, at
different time points after injury, to elicit optimal
repair and regeneration of the tissue.
Another limitation of this study is the unknown
effect of transplanting PICs into diseased muscle,
such as diabetes or muscular dystrophy models,
where the harsh environment and metabolic elements
affect stromal stem cell activity and potency (77).Moving toward clinical application, this warrants
investigation because we may require a combina-
torial approach in order to overcome the harsh
environments that the transplanted PICs will likely
encounter.
CONCLUSIONS
Taken together, these results provide the proof of
concept needed to justify further experimental
development and reﬁnement of this allogeneic
cell therapy approach, which ultimately could lead
to an effective, simple, clinically applicable, and
widely available protocol of tissue repair and
regeneration.
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